Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q1 2023 · 10-Q
Revenue$29.62M$29.62M+26.3% vs Q1 2022 Net Income-$32.77M-$32.77MN/M vs Q1 2022 EPS Diluted-$0.27-$0.27N/M vs Q1 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flow-$24,900,000N/M Free Cash Flowderived-$25,124,000N/M Margins · derivedGross margin43.1%
Operating margin-111.6%+156.6 pt vs Q1 2022
Net margin-110.6%+161.7 pt vs Q1 2022
ended Mar 31, 2023 · filed May 11, 2023 · 41 d after period end